25 April 2018

Blog by Anouck Kluytmans, researcher in early health technology assessment methodology at the Department for Health Evidence.

Accompanied by four lively examples, our Radboudumc proudly presents her vision on healthcare of the future. Personalized and innovative; that is how we’ll become a leading force in sustainable, innovative, and affordable healthcare. In our enthusiasm we seem to be overlooking that these noble causes are often at odds with one another.
 
An academic medical network with regard for the individual patient and innovation that leads us into the future – who could disagree? After all, who would like to be treated a dime a dozen using last century’s technology? The vision of the Radboudumc strongly appeals to our intuition. New is better. Or is it?
 
Perhaps it’s in our nature? We’re so good at attracting innovation – and so poorly equipped to resist. Indeed, patients may punish our institution when we neglect to hop the next big robotics train, or when we bravely disinvest in technology that turned out to be more than we bargained for. Once innovation enters our doors, vested interests and psychological biases will keep it there.
 
In my field of health technology assessment there is emerging awareness that the promise of innovation is limited. To be more precise, the value of innovation is limited by what we’re already achieving in healthcare today and by the constraints in our resources.
 
Mine is not a plea to ignore the future and change nothing. Rather, there’s hard work ahead of us in finding out what and how we want to change first. We find ourselves amidst a wave of innovation, each one more promising than its predecessor. Time and again we see the perfect novel solution to a problem that does not really exist. Impressive, high-level technology whose added value to the real-world patient is unclear at best. At an incremental price to our already overburdened budget, of course, stressing the accessibility of our healthcare system in the future. What I think we need and what I missed so much, is to take that one step back that allows us to reflect.
 
Before asking for solutions we should focus on identifying problems and needs. Where are the biggest windows of opportunity? What kind of innovation do we need? Being brave enough to make choices is one of Radboudumc’s strengths I’ve been missing in this recent strategy acceleration.
 
Innovation, sustainability, and affordability is a challenging triangle to navigate. Keeping the balance requires a priori critical evaluation of which innovations to pursue and why. We need complex, scary, real-world decision-making before swinging our doors wide open.
 
Anouck Kluytmans, MSc
member of the theme Healthcare improvement science
 

Related news items


Young Radboudumc researchers receive grant to engage in bio-medical and health research that is off the beaten path

16 September 2021

The ZonMw Off Road program is once again giving young scientists the opportunity to conduct innovative research in medical and/or health care. This research is off the beaten track and aims to bring about new insights and unexpected breakthroughs for healthcare and healthcare innovation.

read more

Infections increase risk to develop dementia

16 September 2021

In a recently published study, Radboudumc researchers investigated the effects of infectious events on cognitive decline and the development of dementia and its possible structural underpinning using pre- and post-infection MRI of the brain.

read more

Young Investigator Award for Alex Garanto

16 September 2021

Alex Garanto has been honored with the 2021 Mary Ann Liebert, Inc. publishers Young Investigator Award

read more

Depressive symptoms during pregnancy affect baby

16 September 2021

Study in Obstetrics & Gynecology shows associations between depression and adverse birth outcomes

read more

ENABLECARES launches a course on entrepreneurship for PhD candidates and postdocs

15 September 2021

Are you thinking about what to do after your PhD? Want to know more about entrepreneurship? This course gives you insight in many aspects of entrepreneurship and research in industry.

read more

Effectiveness and predictors of response to somatostatin analogues in patients with gastrointestinal angiodysplasias

15 September 2021

Lia Goltstein and colleagues published a study about effectiveness and predictors of response to somatostatin analogues in patients with gastrointestinal angiodysplasias: a systematic review and individual patient data meta-analysis.

read more